Alexandra Kuhlmann-Hogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Kuhlmann-Hogan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Susan M. Kaech
Salk Institute for Biological Studies, La Jolla, CA
56 shared publications - Ziyan Xu
NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California
56 shared publications - Anna-Maria Globig
Allen Institute for Immunology , Seattle, WA
44 shared publications - Camila Robles-Oteíza
Yale School of Medicine 1 Department of Immunobiology New Haven, CT
44 shared publications - Christian M. Metallo
Salk Institute for Biological Studies, La Jolla, CA, USA
44 shared publications - Deborah Ayeni
Departments of Pathology and Internal Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, Connecticut
44 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling
Tumor-associated macrophages (TAM) are a heterogeneous population of myeloid cells that dictate the inflammatory tone of the tumor microenvironment. In this study, we unveiled a mechanism by which scavenger receptor cluster of differentiation 36 (CD36) suppresses TAM inflammatory states. CD36 was upregulated in TAMs and associated with immunosuppressive features, and myeloid-specific deletion of CD36 significantly reduced tumor growth. Moreover, CD36-deficient TAMs acquired inflammatory signatures including elevated type-I IFN (IFNI) production, mirroring the inverse correlation between CD36 and IFNI response observed in patients with cancer. IFNI, especially IFNβ, produced by CD36-deficient TAMs directly induced tumor cell quiescence and delayed tumor growth. Mechanistically, CD36 acted as a natural suppressor of IFNI signaling in macrophages through p38 activation downstream of oxidized lipid signaling. These findings establish CD36 as a critical regulator of TAM function and the tumor inflammatory microenvironment, providing additional rationale for pharmacologic inhibition of CD36 to rejuvenate antitumor immunity.Significance:CD36 in tumor-associated macrophages mediates immunosuppression and can be targeted as a therapeutic avenue for stimulating interferon production and increasing the efficacy of immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling
Tumor-associated macrophages (TAM) are a heterogeneous population of myeloid cells that dictate the inflammatory tone of the tumor microenvironment. In this study, we unveiled a mechanism by which scavenger receptor cluster of differentiation 36 (CD36) suppresses TAM inflammatory states. CD36 was upregulated in TAMs and associated with immunosuppressive features, and myeloid-specific deletion of CD36 significantly reduced tumor growth. Moreover, CD36-deficient TAMs acquired inflammatory signatures including elevated type-I IFN (IFNI) production, mirroring the inverse correlation between CD36 and IFNI response observed in patients with cancer. IFNI, especially IFNβ, produced by CD36-deficient TAMs directly induced tumor cell quiescence and delayed tumor growth. Mechanistically, CD36 acted as a natural suppressor of IFNI signaling in macrophages through p38 activation downstream of oxidized lipid signaling. These findings establish CD36 as a critical regulator of TAM function and the tumor inflammatory microenvironment, providing additional rationale for pharmacologic inhibition of CD36 to rejuvenate antitumor immunity.Significance:CD36 in tumor-associated macrophages mediates immunosuppression and can be targeted as a therapeutic avenue for stimulating interferon production and increasing the efficacy of immunotherapy.
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling
Tumor size (mm 3) 050921 YMR 250K CD4+CD8 delpletion CD36-cKO + anti-CD8/CD4 WT + anti-CD8/CD4 Days post engrafment CD36-cKO
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling
Tumor size (mm 3) 050921 YMR 250K CD4+CD8 delpletion CD36-cKO + anti-CD8/CD4 WT + anti-CD8/CD4 Days post engrafment CD36-cKO